Otsuka Holdings
4578.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥2.47T | ¥2.33T | ¥2.02T | ¥1.74T | ¥1.50T | ¥1.42T |
| Operating income | ¥479.4bn | ¥323.6bn | ¥139.6bn | ¥150.3bn | ¥154.5bn | — |
| Net income (owners) | ¥363.1bn | ¥343.1bn | ¥121.6bn | ¥133.9bnr | ¥125.5bn | ¥148.1bn |
| Total assets | ¥4.20T | ¥3.74T | ¥3.36T | ¥3.10Tr | ¥2.82T | ¥2.63T |
| Net assets / equity | ¥3.10T | ¥2.78T | ¥2.44T | ¥2.26Tr | ¥2.05T | ¥1.88T |
| Operating cash flow | ¥403.6bn | ¥354.6bn | ¥283.2bn | ¥211.8bn | ¥228.9bn | ¥232.8bn |
| EPS (basic) | ¥685.06 | ¥633.76 | ¥224.1 | ¥246.8r | ¥231.32 | ¥273.15 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 4
| Period | Form | Figures |
|---|---|---|
| 2025-01-01 → 2025-12-31 | Annual | 207 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 208 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 217 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 217 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Consumer Products | ¥34.6bn | ¥25.1bn |
| Nutraceuticals | ¥577.6bn | ¥57.7bn |
| Other | ¥112.4bn | ¥8.0bn |
| Pharmaceuticals | ¥1.74T | ¥445.3bn |
| Adjustments & eliminations | — | −¥56.8bn |
| Total | ¥2.47T | ¥536.2bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.